Cargando…

Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients

BACKGROUND: Lymphovascular invasion (LVI) and perineural invasion (PNI) can indicate poor survival outcomes in colorectal cancer, but few studies have focused on stage III colon cancer. The current study aimed to confirm the prognostic value of LVI and PNI and identify patients who could benefit fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Linjie, Deng, Yuxiang, Liu, Songran, Zhang, Weili, Hong, Zhigang, Lu, Zhenhai, Pan, Zhizhong, Wu, Xiaojun, Peng, Jianhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808960/ https://www.ncbi.nlm.nih.gov/pubmed/36593480 http://dx.doi.org/10.1186/s12885-022-10416-7

Ejemplares similares

The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator
por: Xu, Yanbo, et al.
Publicado: (2022)

Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection
por: Peng, Jianhong, et al.
Publicado: (2018)

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
por: Peng, Jianhong, et al.
Publicado: (2019)

Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
por: Pan, Zhizhong, et al.
Publicado: (2018)

Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer
por: Peng, Jianhong, et al.
Publicado: (2017)

Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival
por: Peng, Jianhong, et al.
Publicado: (2017)

High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy
por: Zhou, Wenhao, et al.
Publicado: (2019)

The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
por: Collienne, Maike, et al.
Publicado: (2020)

Feasibility Study of a Modified XELOX Adjuvant Chemotherapy for High-Recurrence Risk Patients With Operated Stage III Colon Cancer
por: Peng, Jianhong, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer
por: Lin, Junzhong, et al.
Publicado: (2022)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer
por: Peng, Jianhong, et al.
Publicado: (2018)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer
por: Uil, Sjoerd H., et al.
Publicado: (2022)

Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy
por: Lee, Kwang Suk, et al.
Publicado: (2015)

The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making
por: Lee, Hayoung, et al.
Publicado: (2022)

Expression of voltage-gated sodium channel Nav1.5 in non-metastatic colon cancer and its associations with estrogen receptor (ER)-β expression and clinical outcomes
por: Peng, Jianhong, et al.
Publicado: (2017)

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis
por: Boyne, Devon J., et al.
Publicado: (2019)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

RCC1 Expression as a Prognostic Marker in Colorectal Liver Oligometastases
por: Deng, Yuxiang, et al.
Publicado: (2021)

Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer
por: Zhang, Fengxiang, et al.
Publicado: (2023)

The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer
por: Kim, Seong-Geun, et al.
Publicado: (2016)

Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502
por: Sadahiro, S., et al.
Publicado: (2015)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Recurrence-Free Survival Outcomes Based on Novel Classification Combining Lymphovascular Invasion, Perineural Invasion, and T4 Status in Stage II–III Colon Cancer
por: Kang, Jae Hyun, et al.
Publicado: (2022)

Prognostic Value of Lymphovascular Invasion in Patients with Stage III Colorectal Cancer: A Retrospective Study
por: Zhong, Jin-Wei, et al.
Publicado: (2019)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
por: Gao, Peng, et al.
Publicado: (2018)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
por: Yoshida, M., et al.
Publicado: (2014)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Updates on Lymphovascular Invasion in Breast Cancer
por: Kuhn, Elisabetta, et al.
Publicado: (2023)

Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
por: Morris, M, et al.
Publicado: (2007)

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
por: Aspinall, Sherrie L, et al.
Publicado: (2015)

Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70
por: Lu, Chieh-Sheng, et al.
Publicado: (2015)

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer
por: van Waalwijk, Maren A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6h01larl0qbmmpcfimm0qqo22p